N Engl J Med 2021;384:111324.ArticlePubMed 81
Uptake in diabetic population The proportion of eligible diabetics who are prescribed the treatments and start taking them
It does not cancel your ability to help another family build theirs

Disclosures: TINGTING LI: Nothing to Disclose, Xuechen Ren: Nothing to Disclose, Joseph Adams: Nothing to Disclose, Amy Gravitte: Nothing to Disclose, Fei Tu: Nothing to Disclose, David L Williams: Nothing to Disclose, Chuanfu Li: Nothing to Disclose, Xiaohui WANG: Nothing to Disclose 698 PREDICTORS OF REVERSAL OF ACUTE ON CHRONIC LIVER FAILURE AND NEED FOR THERAPEUTIC GOALS TO EXTEND TIMELINES BEYOND 90 DAYS Shreyas sarvesh 1 Rajan Vijayaraghavan 1 Ashok Kumar Choudhury 1 Vinod Arora 1 Rakhi Maiwall 1 CHITRANSHU VASHISHTHA 2 Ankur Jindal 3 Shasthry Sm 2 Harsh Tevethia 4 Satender Pal Singh 1 Babu Lal Meena 1 Vikram Bhatia 1 Manoj Sharma 1 Guresh Kumar 1 Shiv Kumar Sarin 1 , 1 Institute of liver and biliary sciences, 2 Institue of liver and biliary sciences, 3 Institue of lliver and biliary sciences, 4 INSTITUTE OF LIVER AND BILIARY SCIENCES(ILBS),NEW DELHI Background: Acute on chronic liver failure (ACLF) syndrome is severe and carries a high short-term mortality

As people gain weight over time, fat infiltrates muscle tissue itself
Current NICE guidance (NG49) does not yet include specific recommendations for GLP-1 use in fatty liver disease outside the context of diabetes or obesity management